Your browser is no longer supported. Please, upgrade your browser.
Settings
BMY Bristol-Myers Squibb Company daily Stock Chart
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E24.55 EPS (ttm)2.54 Insider Own0.16% Shs Outstand1.64B Perf Week-0.02%
Market Cap102.29B Forward P/E19.23 EPS next Y3.25 Insider Trans-5.93% Shs Float1.63B Perf Month2.19%
Income4.23B PEG2.26 EPS next Q0.67 Inst Own71.30% Short Float0.49% Perf Quarter-0.46%
Sales20.57B P/S4.97 EPS this Y184.60% Inst Trans1.32% Short Ratio1.50 Perf Half Y13.02%
Book/sh9.02 P/B6.92 EPS next Y8.35% ROA12.60% Target Price63.82 Perf Year6.41%
Cash/sh4.35 P/C14.36 EPS next 5Y10.86% ROE28.20% 52W Range46.01 - 66.10 Perf YTD6.79%
Dividend1.56 P/FCF62.07 EPS past 5Y4.20% ROI19.80% 52W High-5.58% Beta1.17
Dividend %2.50% Quick Ratio1.50 Sales past 5Y-1.80% Gross Margin72.60% 52W Low35.64% ATR1.10
Employees25000 Current Ratio1.60 Sales Q/Q6.70% Oper. Margin27.30% RSI (14)49.81 Volatility1.74% 1.74%
OptionableYes Debt/Eq0.57 EPS Q/Q-28.20% Profit Margin20.60% Rel Volume1.65 Prev Close62.13
ShortableYes LT Debt/Eq0.47 EarningsJan 25 BMO Payout60.70% Avg Volume5.31M Price62.41
Recom2.40 SMA200.43% SMA50-0.33% SMA2007.44% Volume8,762,223 Change0.45%
Oct-30-17Upgrade SunTrust Hold → Buy
Oct-16-17Downgrade Jefferies Buy → Hold
Sep-12-17Downgrade Hilliard Lyons Long-term Buy → Neutral
Dec-19-16Upgrade Jefferies Hold → Buy
Oct-28-16Reiterated Deutsche Bank Hold $59 → $52
Sep-09-16Reiterated Barclays Equal Weight $75 → $65
Aug-11-16Downgrade Berenberg Buy → Hold
Aug-08-16Reiterated Deutsche Bank Hold $68 → $62
Aug-08-16Downgrade Credit Suisse Outperform → Neutral $63
Aug-05-16Downgrade Morgan Stanley Overweight → Equal-Weight
May-23-16Initiated Hilliard Lyons Neutral
Apr-29-16Reiterated UBS Buy $73 → $80
Apr-29-16Reiterated Barclays Equal Weight $70 → $75
Apr-06-16Initiated Societe Generale Sell $48
Jan-22-16Upgrade Berenberg Hold → Buy
Dec-02-15Upgrade Guggenheim Neutral → Buy
Dec-01-15Reiterated Barclays Equal Weight $55 → $70
Aug-24-15Upgrade Piper Jaffray Underweight → Neutral
Jun-17-15Initiated Piper Jaffray Underweight $60
May-14-15Initiated Berenberg Hold $70
Dec-15-17 01:44PM  Bristol-Myers' Opdivo/Yervoy sBLA for RCC Accepted by FDA Zacks
10:32AM  Orencia and Other Brands in 3Q17 Market Realist
09:02AM  How Cardiovascular Drug Eliquis Performed in 3Q17 Market Realist
08:03AM  Bristol-Myers Squibb Co. breached its 50 day moving average in a Bearish Manner : BMY-US : December 15, 2017 Capital Cube
07:50AM  Pharma Stock Roundup: Teva Announces Major Job Cuts, Lilly Provides 2018 Outlook Zacks
07:33AM  Bristol-Myers Squibbs Virology Products in 3Q17 Market Realist
Dec-14-17 01:30PM  Opdivo: Blockbuster Oncology Drug in 3Q17 Market Realist
01:00PM  How Bristol-Myers Squibbs Oncology Portfolio Performed in 3Q17 Market Realist
10:28AM  A Look at Bristol-Myers Squibbs Revenue in 3Q17 Market Realist
10:28AM  Bristol-Myers Squibbs Valuation in December 2017 Market Realist
Dec-13-17 06:30PM  Bristol-Myers Squibb Granted Exclusive License by Ono Pharmaceutical for Multiple Programs Targeting Immuno-Suppressive Factors in the Tumor Microenvironment Business Wire
05:28PM  U.S. Food and Drug Administration (FDA) Accepts Bristol-Myers Squibbs Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Intermediate- and Poor-Risk Patients with Advanced Renal Cell Carcinoma and Grants Priority Review Business Wire
Dec-12-17 06:04PM  Bristol-Myers (BMY) Reports Positive Data on Leukemia Drug Zacks
12:53PM  ETFs with exposure to Bristol-Myers Squibb Co. : December 12, 2017 Capital Cube
11:12AM  Why Exelixis, Inc. Stock Is Bound to Soar Higher in the Long Run InvestorPlace
Dec-11-17 02:02PM  Biopharma wins in Trump tax bill Yahoo Finance Video
01:06PM  Why Seattle Genetics, Inc. Fell Today Motley Fool
11:58AM  At $62.42, Is It Time To Buy Bristol-Myers Squibb Company (BMY)? Simply Wall St.
10:33AM  Mastercard Inc Leads 6 Dividend Stocks Boosting Payouts InvestorPlace
10:30AM  Seattle Genetics and Bristol-Myers Squibb Highlight Interim Results from Phase 1/2 Study Evaluating the Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Relapsed or Refractory Hodgkin Lymphoma Business Wire
01:32AM  Roche: Tecentriq cocktail slows kidney cancer progression Reuters
Dec-09-17 09:30AM  Sprycel (dasatinib) Added to Standard Chemotherapy Demonstrates Three-Year Survival Benefit in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Business Wire
Dec-08-17 03:59PM  Closing Bell Ringer, December 8, 2017 CNBC Videos
08:01AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
Dec-07-17 04:18PM  [$$] Bristol-Myers: Big Stock Sales and Hardy Buys Barrons.com
04:15PM  Bristol-Myers Squibb Announces Dividend Increase Business Wire
03:57PM  Understanding Allergans Valuation in December 2017 Market Realist
Dec-06-17 01:50PM  Roche to seize leap-frog opportunity in lung cancer Reuters
Dec-05-17 07:51AM  Bristol-Myers Squibb Co. breached its 50 day moving average in a Bearish Manner : BMY-US : December 5, 2017 Capital Cube
06:30AM  Consolidated Research: 2018 Summary Expectations for Skechers U.S.A., Bristol-Myers Squibb, Mastercard, Container Store, Signature Bank, and Bridgepoint Education Fundamental Analysis, Key Performance Indications GlobeNewswire
Dec-04-17 11:56AM  3 Big Stock Charts for Monday: Bank of America Corp (BAC), Bristol-Myers Squibb Co (BMY) and Advance Auto Parts, Inc. (AAP) InvestorPlace
08:01AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
Dec-01-17 06:14PM  Bristol-Myers' Opdivo's Lung Cancer Study Meets Early Success Zacks
10:32AM  What Analysts Recommend for Bristol-Myers Squibb in November 2017 Market Realist
09:33AM  Cancer Space Update: Pfizer's Bavencio Fails in Phase III Zacks
09:02AM  How Bristol-Myers Squibbs Established Products Performed in 3Q17 Market Realist
09:01AM  Understanding Eli Lillys Valuation This November Market Realist
07:32AM  An Update on Bristol-Myers Squibbs Eliquis, Orencia, and Empliciti Market Realist
Nov-30-17 07:05PM  Bristol-Myers Cancer Drug Opdivo Shows Surprising HIV Impact Bloomberg
07:00PM  CheckMate -078, a Pivotal, Multinational Phase 3 Opdivo (nivolumab) Lung Cancer Trial with Predominantly Chinese Patients, Stopped Early for Demonstrating Superior Overall Survival Business Wire
04:59PM  Bristol-Myers Squibb to Take Part at the Citi 2017 Global Healthcare Conference Business Wire
10:33AM  How Is Yervoy Positioned after 3Q17? Market Realist
09:04AM  How Is Bristol-Myers Squibbs Sprycel Positioned Now? Market Realist
08:40AM  In Search Of Novelty: 2017's New FDA Drug Approvals Forbes
07:37AM  How Is Opdivo Positioned after 3Q17? Market Realist
Nov-29-17 04:39PM  How Did Bristol-Myers Squibb Perform in 3Q17? Market Realist
04:15PM  Bristol-Myers Squibb to Present New Data Across a Broad Range of Blood Cancers at the 59th Annual Meeting & Exposition of the American Society of Hematology Business Wire
02:37PM  Understanding the Moat Investing Philosophy Market Realist
11:37AM  Bank of America Acts on Bristol-Myers Squibb and Pfizer GuruFocus.com
Nov-28-17 06:59AM  Bristol-Myers Squibb Awards Golden Tickets for LabCentral to Neutrolis, Remora Therapeutics Business Wire
06:40AM  European Medicines Agency Validates Bristol-Myers Squibbs Type II Variation Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Intermediate- and Poor-Risk Patients with Advanced Renal Cell Carcinoma Business Wire
Nov-27-17 12:25PM  ETFs with exposure to Bristol-Myers Squibb Co. : November 27, 2017 Capital Cube
Nov-24-17 11:14AM  Go With the Gut: Bacteria Is Good for Your Portfolio Barrons.com
Nov-23-17 07:30AM  Analysts Recommendations for Merck in November 2017 Market Realist
Nov-22-17 10:32AM  Inside Exelixiss Label Expansion Collaborations for Cabozantinib Market Realist
06:59AM  Bristol-Myers Squibb to Take Part in Evercore ISI Biopharma Conference Business Wire
Nov-20-17 08:24AM  Roche Cancer Drug Rises To Challenge Merck, Bristol-Myers Forbes
06:00AM  Merck & Co., Inc. Stocks Decline Is a Reason to Get In Now InvestorPlace
Nov-19-17 11:43AM  3 Biotech Stocks to Be Thankful for This Year Motley Fool
Nov-18-17 10:37AM  10 Frightening Lung-Cancer Statistics and 3 Top Companies Looking to Do Something About It Motley Fool
Nov-17-17 10:30AM  Novartis on the Street: Analysts Recommendations in November Market Realist
10:12AM  Why Its Time to Put Pfizer Inc. Stock on Your Watchlist InvestorPlace
08:01AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
Nov-16-17 08:01AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
07:13AM  Pharma Stock Roundup: FDA Nod for AstraZeneca Severe Asthma Drug, Bayer Signs Deal with Loxo Zacks
Nov-15-17 08:01AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
07:36AM  Ultragenyx Seeks An FDA Win For Biologic Therapy Candidate Benzinga
Nov-14-17 02:35PM  Understanding Sanofis Revenues by Segment in 3Q17 Market Realist
Nov-13-17 07:37PM  [$$] Arcus Biosciences Rounds Up $107 Million for Cancer Combination Therapy The Wall Street Journal
03:06PM  Nektar/Bristol-Myers' Combo Trial Positive in Phase I/II Zacks
11:54AM  ETFs with exposure to Bristol-Myers Squibb Co. : November 13, 2017 Capital Cube
10:08AM  Which Will Pfizer Buy? Biogen or Bristol-Myers Squibb Barrons.com
08:28AM  Nektar Therapeutics' stock rockets toward near 17-year high after upbeat trial data MarketWatch
Nov-12-17 11:55PM  First Data for NKTR-214 in Combination with OPDIVO® (nivolumab) for Patients with Stage IV Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers, Including Patients with PD-L1 Negative Status, Revealed at SITC 2017 PR Newswire
Nov-11-17 05:54PM  First Data for NKTR-214 in Combination with OPDIVO® (nivolumab) for Patients with Stage IV Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers, Including Patients with PD-L1 Negative Status, Revealed at SITC 2017 PR Newswire
Nov-10-17 04:13PM  BMS-Pfizer Alliance to Unveil Real-World Data Analyses - Cost, Safety and Comparative Effectiveness Findings Associated with Oral Anticoagulants in Non-Valvular Atrial Fibrillation Business Wire
12:25PM  Are Bristol-Myers Squibb Companys (BMY) Interest Costs Too High? Simply Wall St.
07:00AM  Encouraging Response Observed with Opdivo (nivolumab) Plus Investigational IDO1 Inhibitor, BMS-986205, in Heavily Pre-Treated Patients with Advanced Cancers in Phase 1/2a Study CA017-003 Business Wire
06:30AM  U.S. Food and Drug Administration Expands Approval of Sprycel® (dasatinib) to Include Treatment of Children with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Business Wire
Nov-09-17 11:10AM  Pharma ETFs Down Post Q3 Earnings Zacks
09:01AM  Analysts Recommendations for Celgene in November 2017 Market Realist
08:00AM  Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-CSF-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors Business Wire
Nov-08-17 10:12AM  Infinity (INFI) Q3 Loss Narrower than Expected, View Intact Zacks
06:59AM  Bristol-Myers Squibb to Take Part in Jefferies London Healthcare Conference Business Wire
Nov-07-17 08:35AM  Opdivo Plus Yervoy Combination Delivered Overall Survival Benefit Across PD-L1 Expression Levels in Intermediate- and Poor-Risk Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma Business Wire
08:00AM  Bristol-Myers Squibb to Highlight Clinical and Translational Research at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting Business Wire
07:50AM  New Research: Key Drivers of Growth for Coty, Bristol-Myers Squibb, Carnival, Agenus, Steel Dynamics, and Impax Labs - A Look Behind the Scenes at Consolidated Results, Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
06:02AM  The Only 3 Big Pharma Companies Growing Market Share Motley Fool
Nov-06-17 09:50AM  Outcome Health losing major advertisers following allegations of misleading clients American City Business Journals
09:00AM  Bristol-Myers Squibbs Valuations after Its 3Q17 Earnings Market Realist
08:30AM  BriaCell Provides Clinical Update on its Lead Vaccine Candidate, BriaVax GlobeNewswire
08:09AM  The Zacks Analyst Blog Highlights: Keryx Biopharmaceuticals, Bristol-Myers Squibb, Dynavax Technologies, Heron Therapeutics and Ultragenyx Pharmaceutical Zacks
07:31AM  Bristol-Myers Squibbs Major Developments in 3Q17 Market Realist
07:00AM  Tax Reform: A Back Door To Killing Health Care, Medicare, And More Forbes
06:59AM  Opdivo (nivolumab) Demonstrates Superior Three-Year Survival Benefit for Patients with Previously Treated Advanced Renal Cell Carcinoma (RCC) Business Wire
Nov-05-17 10:00AM  PHOTO ADVISORY: Eric Stonestreet Visits Lung Cancer Alliances Lung Love Walk Houston to Raise Awareness of Cancer Research Business Wire
Nov-03-17 10:31AM  Bristol-Myers Squibbs 3Q17 Earnings: Immunoscience Products Market Realist
09:05AM  Zacks.com highlights: Bristol-Myers Squibb, Quintiles IMS Holdings, Intel, CoreSite Realty and Curtiss-Wright Zacks
09:01AM  Eliquis: A Look at BMYs Blockbuster Cardiovascular Drug in 3Q17 Market Realist
07:31AM  Bristol-Myers Squibbs 3Q17 Earnings: Virology Products Market Realist
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection (HIV). Its products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma. The company's products also comprise Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation; Baraclude to treat chronic hepatitis B virus; Daklinza and Sunvepra to treat hepatitis C virus (HCV); Reyataz and Sustiva to treat HIV; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; and Orencia to treat rheumatoid arthritis. It has collaboration agreements with Portola Pharmaceuticals, Inc., Apexigen, Inc., and Nordic Bioscience; clinical research collaborations with Array BioPharma, Novartis, Clovis Oncology, Inc., and Daiichi Sankyo; and license agreement with Nitto Denko Corporation to develop and commercialize siRNA molecules targeted at HSP47 in vitamin A. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerDec 12Sale63.245,300335,1729,251Dec 13 05:31 PM
LEUNG SANDRAEVP, General CounselDec 04Option Exercise22.14156,5823,466,725584,373Dec 05 06:15 PM
LEUNG SANDRAEVP, General CounselDec 04Sale63.37156,5829,922,601427,791Dec 05 06:15 PM
Bancroft Charles AEVP & Chief Financial OfficerDec 02Option Exercise0.006,4010267,770Dec 05 06:15 PM
Elicker John ESVP, Public Affairs & IRNov 01Option Exercise0.00494068,166Nov 03 04:32 PM
Caldarella Joseph CSVP & ControllerSep 06Sale60.009,340560,40046,297Sep 08 04:31 PM
Nielsen AnneChief Compliance & Ethics OffSep 03Option Exercise0.001,594038,811Sep 06 04:46 PM
Samuels Theodore R. IIDirectorAug 02Buy55.946,000335,62218,000Aug 03 05:08 PM
Gordon MurdoEVP, Chief Commercial OfficerAug 01Option Exercise0.001,510028,751Aug 03 05:07 PM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerMay 14Option Exercise0.0014,551014,551Jun 08 04:51 PM
Caforio GiovanniChairman and CEOMay 05Option Exercise0.008,0400180,458May 09 04:32 PM
ANDREOTTI LAMBERTODirectorApr 07Sale53.2217,000904,791935,571Apr 10 05:09 PM
ANDREOTTI LAMBERTODirectorApr 06Sale53.2917,000905,964952,571Apr 10 05:09 PM
JUDGE ANN POWELLSVP, Global Human ResourcesApr 01Option Exercise0.001,554044,125Apr 04 07:17 PM
ANDREOTTI LAMBERTODirectorMar 28Sale56.2017,000955,369969,112Mar 29 06:19 PM
ANDREOTTI LAMBERTODirectorMar 27Sale56.1417,000954,451986,112Mar 29 06:19 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 17Sale56.495,000282,47021,483Mar 21 04:35 PM
Caldarella Joseph CSVP & ControllerMar 15Sale57.298,096463,77955,637Mar 22 06:20 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 14Sale56.7515,000851,22026,483Mar 16 04:37 PM
Caforio GiovanniChief Executive OfficerMar 10Option Exercise0.0087,6040199,229Mar 14 08:32 PM
Blin EmmanuelSVP, Chief Strategy OfficerMar 10Option Exercise0.0013,275023,690Mar 14 08:32 PM
Cuss Francis MEVP & CSOMar 10Option Exercise0.0066,7260346,770Mar 14 08:33 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0065,4240451,862Mar 14 08:33 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0031,7210119,772Mar 14 08:31 PM
Gordon MurdoEVP, Chief Commercial OfficerMar 10Option Exercise0.0025,592035,898Mar 14 08:31 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0087,3240289,293Mar 14 08:31 PM
Nielsen AnneChief Compliance & Ethics OffMar 10Option Exercise0.0013,696041,215Mar 14 08:30 PM
ANDREOTTI LAMBERTODirectorMar 10Option Exercise0.00102,17401,060,105Mar 14 08:30 PM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0031,513052,546Mar 14 08:29 PM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0018,799073,284Mar 14 08:29 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0033,271051,898Mar 14 08:30 PM
Caldarella Joseph CSVP & ControllerMar 10Option Exercise0.0015,484068,911Mar 14 08:29 PM
LEUNG SANDRAEVP, General CounselMar 06Sale57.0292,4055,268,563395,658Mar 07 04:39 PM
LEUNG SANDRAEVP, General CounselMar 03Option Exercise27.01116,1003,135,861488,063Mar 07 04:39 PM
Bancroft Charles AEVP & Chief Financial OfficerFeb 28Option Exercise27.0122,598610,372212,516Mar 01 04:47 PM
Samuels Theodore R. IIDirectorFeb 27Buy56.7712,000681,24012,000Mar 01 04:47 PM
ANDREOTTI LAMBERTODirectorJan 30Option Exercise27.01100,0002,701,000957,931Feb 01 04:43 PM
Elicker John ESVP, Public Affairs & IRJan 03Option Exercise0.00950056,232Jan 05 04:37 PM